FibroBiologics (FBLG) Fundamental Analysis: Revenue, Earnings & Valuation

1.78 / 10

Underperform

Fundamentally the stock underperforms, scoring 1.78/10. Positive points include accounts receivable turnover and interest coverage, yet revenue growth is offset by high inventory turnover, weak asset metrics and low profitability ratios, indicating a challenging financial profile.

Analysis Checks(6/10)

Revenue-MV

Value-0.08

Score3/3

Weight66.25%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value134.75

Score2/3

Weight3.52%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-3.76%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-3.73%

1M Return-0.65%

PB-ROE

Value-0.19

Score0/3

Weight27.24%

1M Return3.80%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-8.47%

1M Return-1.54%

Fixed assets turnover ratio

Value9771.06

Score1/3

Weight-6.98%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-4.20%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-4.13%

1M Return-0.74%

Asset-MV

Value-0.55

Score0/3

Weight34.26%

1M Return4.88%

Is FBLG fundamentally strong?

FBLG scores 1.78/10 on fundamentals and holds a Premium valuation at present. Backed by its -419.44% ROE, 0.00% net margin, -0.96 P/E ratio, 2.92 P/B ratio, and -23.53% earnings growth, these metrics solidify its Underperform investment rating.